Novartis’s Cosentyx gains U.S. Food and Drug Administration approval for patients aged 12+ with moderate-to-severe Hidradenitis Suppurativa. Novartis announced today that Cosentyx® (secukinumab) received US Food and Drug Administration (FDA) approval for treating pediatric patients 12 years and older with moderate to severe hidradenitis…
WuXi Biologics Earns Multiple Asia-Pacific Biopharma Excellence Awards for Advancements in Bioprocessing, Manufacturing Quality, and Digital Innovation WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won six prestigious awards…
Johnson & Johnson Secures U.S. Food and Drug Administration Approval for TECNIS PureSee Intraocular Lens, Expanding Vision Care Options for U.S. Cataract Patients Johnson & Johnson announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth…
GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications GoodRx the leading platform for prescription savings in the U.S., announced a new collaboration with Viatris, a global healthcare company, to make 17 of its established…
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan Curatis Holding AG and Neupharma Co., Ltd. a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology…
Verasonics Announces Vantage® NXT Platform Update Featuring Encoder Integration, Focused Ultrasound 2D/3D Software, New 8 MHz Matrix Array Transducer Verasonics, Inc., the leader in research ultrasound, announced the release of a significant update for its Vantage NXT Research Ultrasound platform. The release introduces advanced…
Butterfly Network Appoints David Horsley as Senior Vice President, Innovation – Butterfly Embedded™ Butterfly Network, Inc. a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, announced the appointment of David Horsley, Ph.D. as Senior Vice President…
Obesity Drug Olatorepatide, Licensed by Regeneron Pharmaceuticals, Shows Positive Phase 3 Outcomes in Chinese Patients Regeneron Pharmaceuticals, Inc. today announced Hansoh Pharmaceutical Group Company Limited has shared positive topline data from its Phase 3 trial in Chinese patients evaluating olatorepatide for the…
Novo Nordisk broadens U.S. patient access to FDA-approved semaglutide treatments through Hims & Hers following a strategic shift in its U.S. GLP-1 business approach. Novo Nordisk today announced it has reached an agreement with telehealth company Hims & Hers that…
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed or Refractory Multiple Myeloma Halozyme Therapeutics has announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for the use of TECVAYLI (teclistamab-cqyv)…
NEJM Publishes Phase III ALLEGORY Results Showing Gazyva Reduces Disease Activity in Common Lupus Genentech, a member of the Roche Group, has announced that detailed results from the Phase III ALLEGORY clinical trial evaluating Gazyva (obinutuzumab) in adults with Systemic…
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia DiaMedica Therapeutics Inc. a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that…